ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced strategic headcount reduction and provided an update on the merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad Medisys. “Whi ...